<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789892</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-10012</org_study_id>
    <secondary_id>NCI-2012-00530</secondary_id>
    <nct_id>NCT01789892</nct_id>
  </id_info>
  <brief_title>Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer</brief_title>
  <official_title>FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether giving an anti-inflammatory medication
      (corticosteroid) prior to a positron emission tomography scan (PET) scan may reduce or
      eliminate false findings related to inflammation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess whether premedication with a corticosteroid may reduce false positive findings
      on fluorodeoxyglucose (fludeoxyglucose F 18 [FDG[) PET/computed tomography (CT) scans in lung
      cancer patients, by reducing radiotracer uptake in thoracic lymph nodes related to
      inflammation.

      OUTLINE:

      Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone
      intravenously (IV) and then undergo a second FDG PET/CT scan.

      After completion of study treatment, patients are followed up for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no patient accrual
  </why_stopped>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous standardized uptake values (SUV)</measure>
    <time_frame>Within 1-14 days of first scan</time_frame>
    <description>The SUV on the first and second PET scans will be recorded and summarized on a receiver operating characteristic (ROC) curve. We will explore the ROC curve for percent change in SUV or uptake ratio from the first to the second scan. We will explore thresholds for SUV and uptake values on the ROC curve by determining the values of acceptable combinations of true positive fractions (TPF) and false positive fractions (FPFs). We will use regression methods to adjust for possible confounding patient demographics, disease severity and disease history.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (methylprednisolone and FDG PET/CT scan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (methylprednisolone and FDG PET/CT scan)</arm_group_label>
    <other_name>Depo-Medrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>MePRDL</other_name>
    <other_name>Solu-Medrol</other_name>
    <other_name>Wyacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Undergo FDG PET/CT scan</description>
    <arm_group_label>Diagnostic (methylprednisolone and FDG PET/CT scan)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo FDG PET/CT scan</description>
    <arm_group_label>Diagnostic (methylprednisolone and FDG PET/CT scan)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Undergo FDG PET/CT scan</description>
    <arm_group_label>Diagnostic (methylprednisolone and FDG PET/CT scan)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient undergoing initial staging of biopsy proven lung cancer (all cancer stages
             included)

          -  Undergone clinical FDG PET/CT scan within 14 days of enrollment

        Exclusion Criteria:

          -  Prisoners

          -  Diabetic patients (on insulin, on oral hypoglycemic, or fasting glucose &gt; 180 mg/dl)

          -  Serious infection within 14 days of enrollment

          -  Known hypersensitivity to methylprednisolone

          -  Viral skin lesions

          -  Immunocompromised ANC(absolute neutrophil count &lt; 1000/microliter)

          -  Pregnant/nursing

          -  History of tuberculosis or systemic fungal disease

          -  History of steroid psychosis

          -  Current peptic ulcer disease or diverticulitis

          -  Corticosteroid use within 14 days of enrollment (including inhaled steroids)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2013</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>David Barker</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

